Oncimmune (LON:ONC) Shares Down 12.5% – Here’s Why

Oncimmune Holdings plc (LON:ONC) shares were down 12.5% on Wednesday . The company traded as low as GBX 2.10 ($0.03) and last traded at GBX 2.38 ($0.03). Approximately 620,135 shares were traded during trading, a decline of 2% from the average daily volume of 634,587 shares. The stock had previously closed at GBX 2.72 ($0.03).

Oncimmune Price Performance

The stock has a market capitalization of £2.49 million, a P/E ratio of 0.25 and a beta of 1.19. The company has a debt-to-equity ratio of -412.06, a current ratio of 1.14 and a quick ratio of 0.63. The company’s 50-day simple moving average is GBX 11.02 and its 200-day simple moving average is GBX 14.37.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.